Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954198 · ClinicalTrials.gov registry record · NA
Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients
A NA study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02954198 is a NA study that has completed, run by Medical University of South Carolina. The registered enrollment target is 40 participants.
The verdict
NCT02954198, a NA study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
With the availability of well-studied once-daily formulations of tacrolimus, the ability to achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may finally be achievable and have the potential to optimize immunosuppression safety and efficacy in kidney transplantation.
Interventions
- DRUG Everolimus
- DRUG Prednisone
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2018-12-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954198
The ClinicalTrials.gov registry entry for NCT02954198 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Everolimus is the first listed.
NCT02954198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02954198 about?
NCT02954198 is a clinical study titled "Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients". With the availability of well-studied once-daily formulations of tacrolimus, the ability to achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may finally be achievable and have the potential to optimize immunosuppression safety and efficacy in kidney transplantat...
What is the current status of trial NCT02954198?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2016-12-01. Estimated completion is 2018-12-27.
What interventions are being tested in trial NCT02954198?
The interventions under investigation include: Everolimus (DRUG), Prednisone (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT02954198?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.